Computer-aided design of selective COX-2 inhibitors: comparative molecular field analysis and docking studies of some 3,4-diaryloxazolone derivatives

被引:19
作者
Desiraju, GR [1 ]
Sarma, JARP
Raveendra, D
Gopalakrishnan, B
Thilagavathi, R
Sobhia, ME
Subramanya, HS
机构
[1] Univ Hyderabad, Sch Chem, Hyderabad 500046, Andhra Pradesh, India
[2] Indian Inst Chem Technol, Mol Modelling Grp, Organ Div, Hyderabad 500007, Andhra Pradesh, India
[3] Natl Inst Pharmaceut Educ & Res, Dept Med Chem, Sas Nagar 160062, Punjab, India
[4] Cent Drug Res Inst, Div Membrane Biol, Lucknow 226001, Uttar Pradesh, India
关键词
selective COX-2 inhibitors; diaryloxazolones; CoMFA; docking studies;
D O I
10.1002/poc.393
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The recent discovery of a second, inducible isoform of cyclooxygenase, COX-2, has stimulated the search for highly selective non-steroidal anti-inflammatory drugs (NSAIDs). These NSAIDs have the ability to treat pain and inflammation caused by arthritis with less risk of gastrointestinal or renal toxicity. We report here the results of 3D-quantitative structure-activity relationship and docking studies, performed on a series of 3,4-diaryloxazolones. Comparative moleculer field analysis studies provided a good model with cross-validated and conventional r(2) values of 0.688 and 0,969 respectively for 24 analogues in the training set with six components. Docking studies with both COX-1 and COX-2 indicate good selectivity for COX-2. The binding energies between COX-2 and some of the most active oxazolones are comparable to those of celecoxib or rofecoxib. These compounds adopt similar orientations and form similar sets of hydrogen bonds involving the sulfonyl group of the ligand and His 90, Leu 352, Ser 353, Arg 513, Phe 518 and Ser 530 residues of the receptor. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:481 / 487
页数:11
相关论文
共 36 条
[1]  
ABOLA EE, 1987, CRYSTALLOGRAPHIC DAT, P171
[2]   Structure-based design of COX-2 selectivity into flurbiprofen [J].
Bayly, CI ;
Black, WC ;
Léger, S ;
Ouimet, N ;
Ouellet, M ;
Percival, MD .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (03) :307-312
[3]  
Churchill L., 1996, Inflammopharmacology, V4, P125, DOI 10.1007/BF02735467
[4]  
Clark M., 1990, TETRAHEDRON COMPUT M, V3, P47, DOI DOI 10.1016/0898-5529(90)90120-W
[5]   Three-dimensional quantitative structural activity relationship (3D-QSAR) studies of some 1,5-diarylpyrazoles: Analogue based design of selective cyclooxygenase-2 inhibitors [J].
Desiraju, GR ;
Gopalakrishnan, B ;
Jetti, RKR ;
Raveendra, D ;
Sarma, JARP ;
Subramanya, HS .
MOLECULES, 2000, 5 (07) :945-955
[6]   2-heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors [J].
Dubé, D ;
Brideau, C ;
Deschênes, D ;
Fortin, R ;
Friesen, RW ;
Gordon, R ;
Girard, Y ;
Riendeau, D ;
Savoie, C ;
Chan, CC .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (12) :1715-1720
[7]   Structural basis for selective inhibition of COX-2 by nimesulide [J].
Fabiola, GF ;
Pattabhi, V ;
Nagarajan, K .
BIOORGANIC & MEDICINAL CHEMISTRY, 1998, 6 (12) :2337-2344
[8]   Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2) [J].
García-Nieto, R ;
Pérez, C ;
Gago, F .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2000, 14 (02) :147-160
[9]   ETODOLAC SELECTIVELY INHIBITS HUMAN PROSTAGLANDIN-G/H-SYNTHASE-2 (PGHS-2) VERSUS HUMAN PGHS-1 [J].
GLASER, K ;
SUNG, ML ;
ONEILL, K ;
BELFAST, M ;
HARTMAN, D ;
CARLSON, R ;
KREFT, A ;
KUBRAK, D ;
HSIAO, CL ;
WEICHMAN, B .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 281 (01) :107-111
[10]   HUMAN CYCLOOXYGENASE-2 CDNA [J].
HLA, T ;
NEILSON, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (16) :7384-7388